Blogs

Latest Blogs

[wd_asp id=2]

Antibody‑Drug Conjugates (ADCs): The Tipping Point

May 28, 2026

The field of antibody-drug conjugates (ADCs) is entering an exciting era, and there is no shortage of writing today about where this modality is headed:…

Quantitative Analysis of Oligonucleotides: An out of the box LC-MS/MS approach

March 5, 2025

Oligonucleotide therapeutics have revolutionised the field of medicine over the last decade due to their potential for treating a broad…

The Next Frontier for CAR T-Cell Therapy: Shifting Gears to Autoimmune Conditions

February 18, 2025

CAR T-cell therapy has transformed cancer treatment, offering new hope for patients with aggressive B cell malignancies like acute lymphoblastic…

Identifying biomarkers of success: Integrated bioanalysis for glioblastoma CAR-T cell clinical trials

October 18, 2024

Glioblastoma remains one of the most aggressive and treatment-resistant cancers. Standard therapies often fail, leaving patients with limited options.…

Allogeneic CAR T cell therapies: A major step forward

October 9, 2024

In a groundbreaking clinical trial, three individuals suffering from severe autoimmune diseases have entered remission following a novel CAR T…

A controlled detonation: Targeted antibody drug conjugates (ADCs) for oncology

September 17, 2024

Are antibody-drug conjugates (ADCs), principally comprised of an antibody, a cytotoxic payload and a linker, the next therapeutic modality of…

The mpox outbreak: Variants, transmission and the boost for vaccine manufacturers

September 5, 2024

Following Covid-19, the world is collectively on high alert for anything that could indicate another pandemic. What do we know…